Everand Logo

Welcome to Everand!

  • STAT

    LISTEN: A genome-editing flop, a Celgene Senate hopeful, and a live audience

    Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? Find out on the latest episode of our podcast, "The Readout LOUD."
    by Damian Garde and Rebecca Robbins and Adam Feuerstein Sep 06, 2018 1 minute

    Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma?

    We discuss all that

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
    And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
    The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

    Related Books & Audiobooks